Find Out More
About the
THRIVE-132 Study

Please complete the form below and we will contact you with more information.

Your answers will not be stored or shared.

Does your patient have a confirmed diagnosis of sickle cell disease (SCD)?*

Are they 16 years old or older?*

Have they experienced between 2 and 10 VOCs within the past 12 months?*

If they are taking hydroxyurea (HU), L-glutamine, or OXBRYTA® (voxelotor), have they been on a stable dose for at least 30 days?*

Are they receiving regularly scheduled red blood cell (RBC) transfusion therapy (also termed chronic, prophylactic, or preventative transfusion)?*

Are they taking or have they received ADAKVEO® (crizanlizumab) within the past 90 days?*

Submit

Submit